ClinicalTrials.gg
Not yet recruitingNCT04570228Updated Apr 1, 2022

TROPHY PAH Pivotal Study - TReatment of Pulmonary HYpertension for PAH Pivotal Study

An interventional study of Pulmonary artery denervation and Sham procedure in Pulmonary Arterial Hypertension, sponsored by SoniVie Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-01.

Sponsored by SoniVie Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Theis is a prospective, multicenter, blinded, randomized sham controlled pivotal clinical trial with a crossover at 6M, to assess the safety and effectiveness of pulmonary artery denervation with the TIVUS™ System in subjects with PAH. The study will assess improved and/or maintained exercise tolerance in patients with PAH through the analysis of exercise tolerance, hemodynamic changes, clinical worsening and the quality of life who got treated by the TIVUS system.

02

Conditions studied

  • Pulmonary Arterial Hypertension
03

In context

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

This study's planned enrollment of 205 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

SoniVie Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written to participate in the study obtained from the subject, according to local regulations, prior to initiation of any study mandated procedure.
  2. Male or female ≥ 18 years of age at the time of screening
  3. Subject with known pulmonary arterial hypertension (PAH), which has been diagnosed as idiopathic PAH, connective tissue disease PAH, anorexigen induced, familial PAH or corrected congenital heart defects more than 1 year prior to enrollment, confirmed by right heart catheterization performed prior to screening and showing all of the following:

    • Mean pulmonary artery pressure (mPAP) ≥25 mmHg at rest
    • Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) ≤15 mmHg
    • Pulmonary vascular resistance (PVR) at rest >3 Wood units (240 dyne*s/cm\^5)
  4. Subject is on maximally tolerated medical therapy for PAH, as determined by his PAH physician
  5. Subject is adhering to a stable drug regimen (i.e., with no changes of dose or medication for a minimum of 3 months prior to enrollment)
  6. Subject is able to tolerate IV contrast used for the angiograms during treatment
  7. Subject is WHO functional class II or III

Exclusion criteria

Exclusion Criteria:

  1. Subject is treated with parenteral prostanoids and has not been on a stable dose for at least 3 months
  2. Subjects with portal-pulmonary hypertension, Group 2, 3 and 4 PH
  3. Pregnant women or women planning a pregnancy within 12 months of study enrolment
  4. Subject with significant co-morbid conditions which, at the discretion of the PI, are deemed to prohibit study entry
  5. Subject with of less than a year
  6. Concurrent enrollment in another device or drug trial except for observational studies (unless specifically approved by the sponsor)
  7. Subject with pulmonary artery anatomy that precludes treatment with the TIVUS System
  8. Subject who has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident in the previous 6 months
  9. Subject experiencing a current episode of acute decompensated heart failure
  10. Subject who has cardiac pacemakers/ICD/CRT-D that were implanted fewer than three months prior to enrollment.
  11. Subject who has implantable Cardiomems device, or other implanted device that might be for therapeutic ultrasound energy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
205 participants (estimated)

Study arms

  • Active comparator
    Treatment group

    Pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization and pulmonary artery angiography.

    Device: Pulmonary artery denervation

  • Sham comparator
    Sham control group

    A sham treatment of pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization pulmonary artery angiography. The sham procedure will be identical to the denervation procedure, with the only exception that the procedure will use a sham setting on the control console.

    Device: Sham procedure

Interventions

  • DevicePulmonary artery denervation

    The TIVUS system will be used for pulmonary artery denervation using non focused ultrasound

  • DeviceSham procedure

    A sham procedure would be performed using the TIVUS system without delivering the non focused ultrasound

06

What researchers measure

Primary outcomes

  1. 6 minute walking distance (6MWD)

    Statistical difference in 6MWD between the treated group and the sham control group

    Time frame: 6 months

  2. The rate of procedure and treatment related SAEs reported

    Time frame: 12 months

Secondary outcomes

  1. Statistical difference between the treated group and the sham control group in exercise tolerance as measured using the change in activity parameters using the Actigraph Centrepoint watch

    Time frame: 6 months

  2. Difference between time to clinical worsening event between the treated group and the sham control group

    Time frame: 6 months

  3. Difference between the number of clinical worsening events between the treated group and the sham control group

    The definition of clinical worsening events includes: all cause death, hospitalization for worsening PAH, lung/heart transplant, arterial septostomy, initiation of parenteral prostanoid therapy, change in dose and/or number of PAH specific medication. Each event will be counted as a single event and per each patient the total number of events will be recorded

    Time frame: 6 months

  4. Difference between the treated group and the sham control group in resting mean right atrial pressure (mRAP)

    Time frame: 6 months

  5. Difference between the treated group and the sham control group in resting mean pulmonary artery pressure (mPAP)

    Time frame: 6 months

  6. Difference between the treated group and the sham control group in resting pulmonary vascular resistance (PVR)

    Time frame: 6 months

  7. Difference between the treated group and the sham control group in resting cardiac index (CI)

    Time frame: 6 months

  8. Difference between the treated group and the sham control group in Quality of Life (QOL) score using the SF36 questionnaire

    The SF36 is a 0-100 score, the lower the score is the lower the quality of life is, so that zero is equivalent to maximum disability and a score of 100 is equivalent to no disability at all

    Time frame: 6 months

  9. Difference between the treated group and the sham control group of NT-pro-BNP levels

    Time frame: 6 months

  10. Difference between the treated group and the sham control group in patients' clinical pulmonary arterial hypertension condition defined by worsening of World Health Organization (WHO) functional class

    PAH patient's WHO functional class is a scale of 1 to 4 based on the symptoms patient experience when doing everyday activities, were Functional Class 1 and 2 are associated with limited effect on patient activity and lower risk status, and Functional Class 3 and 4 are associated with limited activity and higher risk status

    Time frame: 6 months

  11. Percent of patients who improve or maintain their exercise tolerance (as measured by 6MWD and actigraphy)

    Time frame: 6 months

Other outcomes

  1. Clinical change of pulmonary arterial hypertension condition defined by escalation of PAH specific drug therapy

    Change in the dose of medication

    Time frame: 6, 12, 24, 36 month

  2. Clinical change of pulmonary arterial hypertension condition defined by escalation of PAH specific drug therapy

    Change in the number of PAH specific medication

    Time frame: 6, 12, 24, 36 month

  3. Clinical change of pulmonary arterial hypertension condition defined by escalation of concomitant drug therapy

    Change in the number of concomitant medication

    Time frame: 6, 12, 24, 36 month

  4. Clinical change of pulmonary arterial hypertension condition defined by escalation of concomitant drug therapy

    Change in dose of a medication

    Time frame: 6, 12, 24, 36 month

  5. Clinical change of pulmonary arterial hypertension condition defined by change from baseline of ECG parameters demonstrating initiation or worsening of heart block

    Heart block is defined as long PR interval, wide or narrow QRS complex and/or QRS complex in various leads are oriented rightward and anteriorly. Heart block will be noted as either present or not present. Any change from baseline will be noted.

    Time frame: 6, 12, 24, 36 month

  6. Clinical change of pulmonary arterial hypertension condition defined by change from baseline of ECG parameters indicating initiation or worsening of arrhythmia

    Arrhythmia is defined when the P-P interval and/or R-R interval has differences of more than 10% and/or there are no visible P waves and/or irregularly irregular QRS complex is present. Arrhythmia will be noted as either present or not present. Any change from baseline will be noted.

    Time frame: 6, 12, 24, 36 month

  7. Clinical change of pulmonary arterial hypertension condition defined by change from baseline of ECG parameters indicating initiation or worsening of right ventricular hypertrophy (RVH)

    Right ventricular hypertrophy is when the following are present: right axis deviation \> 90 degrees, tall R-waves in RV leads; deep S-waves in LV leads, slight increase in QRS duration and ST-T changes directed opposite to QRS direction (i.e., wide QRS/T angle). Right ventricular hypertrophy will be noted as either present or not present. Any change from baseline will be noted.

    Time frame: 6, 12, 24, 36 month

  8. Clinical change of pulmonary arterial hypertension condition defined by change from baseline of ECG parameters indicating initiation or worsening of axis deviation

    Axis deviation is present when QRS axis is greater than +90° or smaller than +30°. Axis deviation will be noted as either present or not present. Any change from baseline will be noted.

    Time frame: 6, 12, 24, 36 month

  9. Change from baseline of 6MWD

    Time frame: 12, 24, 36 month

  10. Change from baseline of NT-pro BNP levels

    Time frame: 12, 24, 36 month

  11. Change from baseline of actigraphy measures as will be measured using an Actigraph Centrepoint Insight Activity monitor

    Time frame: 12, 24, 36 month

  12. Change from baseline of Quality of Life (QOL) score using the SF36 questionnaire

    PAH patient's WHO functional class is a scale of 1 to 4 based on the symptoms patient experience when doing everyday activities, were Functional Class 1 and 2 are associated with limited effect on patient activity and lower risk status, and Functional Class 3 and 4 are associated with limited activity and higher risk status

    Time frame: 12, 24, 36 month

  13. Survival or the cause of mortality

    Time frame: 6, 12, 24, 36 month

  14. Amount of Hospitalizations events due to pulmonary arterial hypertension

    Time frame: 6, 12, 24, 36 month

  15. Number of patients with clinical worsening of PAH condition resulting with interventional or surgical procedures, such as heart/lung transplant or atrial septostomy.

    Time frame: 6, 12, 24, 36 month

  16. Clinical change of pulmonary arterial hypertension condition defined by worsening of patients' WHO functional class

    PAH patient's WHO functional class is a scale of 1 to 4 based on the symptoms patient experience when doing everyday activities, were Functional Class 1 and 2 are associated with limited effect on patient activity and lower risk status, and Functional Class 3 and 4 are associated with limited activity and higher risk status

    Time frame: 12, 24, 36 month

  17. Clinical change of pulmonary arterial hypertension condition defined by escalation of concomitant drug therapy

    Change in the dose of medication

    Time frame: 6, 12, 24, 36 month

  18. Clinical change of pulmonary arterial hypertension condition defined by escalation of concomitant drug therapy

    Change in the number of concomitant medications

    Time frame: 6, 12, 24, 36 month

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2023; primary completion for Dec 2023, 11 months later.

Of 65 interventional studies with no phase under Pulmonary Arterial Hypertension, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2020
First posted
Sep 30, 2020
StartEst.
Jan 1, 2023
Primary completionEst.
Dec 1, 2023
CompletionEst.
Dec 1, 2025
Last update
Apr 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04570228
Lead sponsor
SoniVie Inc.
Responsible party
Sponsor
First posted
Sep 30, 2020
Start date
Jan 1, 2023 (estimated)
Primary completion
Dec 1, 2023 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Apr 1, 2022

Study contacts

Dalit Shav, PhD
Contact
info@sonivie.com
+19784600773
Charles S Carignan, MD
Contact
info@sonivie.com
+19784600773

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion